Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone

Abstract

Receptor activator of NF-κB ligand (RANKL) is a multifunctional cytokine known to affect immune and skeletal systems, as well as oncogenesis and metastasis1,2,3,4. RANKL is synthesized as a membrane-bound molecule, and cleaved into its soluble form by proteases5,6,7. As the soluble form of RANKL does not contribute greatly to bone remodelling or ovariectomy-induced bone loss8, whether soluble RANKL has a role in pathological settings remains unclear. Here we show that soluble RANKL promotes the formation of tumour metastases in bone. Mice that selectively lack soluble RANKL (Tnfsf11ΔS/ΔS)5,6,7,9 have normal bone homoeostasis and develop a normal immune system but display markedly reduced numbers of bone metastases after intracardiac injection of RANK-expressing melanoma and breast cancer cells. Deletion of soluble RANKL does not affect osteoclast numbers in metastatic lesions or tumour metastasis to non-skeletal tissues. Therefore, soluble RANKL is dispensable for physiological regulation of bone and immune systems, but has a distinct and pivotal role in the promotion of bone metastases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Tnfsf11ΔS/ΔS mice do not exhibit any discernible osteopetrotic phenotype.
Fig. 2: Soluble RANKL is dispensable for lymph node development and mTEC differentiation.
Fig. 3: Soluble RANKL promotes bone metastasis of B16F10 melanoma cells without affecting osteoclastogenesis.
Fig. 4: Contribution of soluble RANKL to bone metastasis of breast cancer cells.

Data availability

The data that support the plots within this paper and other findings of this study are available from the corresponding authors upon reasonable request.

References

  1. 1.

    Okamoto, K. et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol. Rev. 97, 1295–1349 (2017).

    CAS  Article  Google Scholar 

  2. 2.

    Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1999).

    CAS  Article  Google Scholar 

  3. 3.

    Walsh, M. C. & Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front. Immunol. 5, 1–11 (2014).

    CAS  Article  Google Scholar 

  4. 4.

    Sigl, V., Jones, L. P. & Penninger, J. M. RANKL/RANK: from bone loss to the prevention of breast cancer. Open Biol. 6, 160230 (2016).

    Article  Google Scholar 

  5. 5.

    Lum, L. et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274, 13613–13618 (1999).

    CAS  Article  Google Scholar 

  6. 6.

    Nakashima, T. et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275, 768–775 (2000).

    CAS  Article  Google Scholar 

  7. 7.

    Hikita, A. et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J. Biol. Chem. 281, 36846–36855 (2006).

    CAS  Article  Google Scholar 

  8. 8.

    Xiong, J. et al. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat. Commun. 9, 2909 (2018).

    Article  Google Scholar 

  9. 9.

    Nagashima, K. et al. Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat. Immunol. 18, 675–682 (2017).

    CAS  Article  Google Scholar 

  10. 10.

    Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000).

    CAS  Article  Google Scholar 

  11. 11.

    Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).

    CAS  Article  Google Scholar 

  12. 12.

    Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).

    CAS  Article  Google Scholar 

  13. 13.

    Danks, L. et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann. Rheum. Dis. 75, 1187–1195 (2016).

    CAS  Article  Google Scholar 

  14. 14.

    Onal, M. et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 287, 29851–29860 (2012).

    CAS  Article  Google Scholar 

  15. 15.

    Guerrini, M. M. et al. Inhibition of the TNF family cytokine RANKL prevents autoimmune inflammation in the central nervous system. Immunity 43, 1174–1185 (2015).

    CAS  Article  Google Scholar 

  16. 16.

    Lacey, D. L. et al. Osteoprotegrin ligand is cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176 (1998).

    CAS  Article  Google Scholar 

  17. 17.

    Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597–3602 (1998).

    CAS  Article  Google Scholar 

  18. 18.

    Takahashi, N. et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600–2602 (1988).

    CAS  Article  Google Scholar 

  19. 19.

    Miyamoto, T. et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand. Blood 96, 4335–4343 (2000).

    CAS  PubMed  Google Scholar 

  20. 20.

    Udagawa, N. et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478–3484 (2000).

    CAS  Article  Google Scholar 

  21. 21.

    Findlay, D. M. & Atkins, G. J. Relationship between serum RANKL and RANKL in bone. Osteoporos. Int. 22, 2597–2602 (2011).

    CAS  Article  Google Scholar 

  22. 22.

    Tsukasaki, M. et al. Host defense against oral microbiota by bone-damaging T cells. Nat. Commun. 9, 1–11 (2018).

    CAS  Article  Google Scholar 

  23. 23.

    Onder, L. et al. Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity 47, 80–92.e4 (2017).

    CAS  Article  Google Scholar 

  24. 24.

    Hikosaka, Y. et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29, 438–450 (2008).

    CAS  Article  Google Scholar 

  25. 25.

    Roodman, G. D. & Dougall, W. C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat. Rev. 34, 92–101 (2008).

    CAS  Article  Google Scholar 

  26. 26.

    Croucher, P. I., McDonald, M. M. & Martin, T. J. Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer 16, 373–386 (2016).

    CAS  Article  Google Scholar 

  27. 27.

    Esposito, M., Guise, T. & Kang, Y. The biology of bone metastasis. Cold Spring Harb. Perspect. Med. 8, a031252 (2018).

    Article  Google Scholar 

  28. 28.

    Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006).

    CAS  Article  Google Scholar 

  29. 29.

    Sanchez-Sweatman, O. H., Lee, J., Or, F. W. & Singh, G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur. J. Cancer 33, 918–925 (1997).

    CAS  Article  Google Scholar 

  30. 30.

    Nakai, Y. et al. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7, 1 (2019).

    CAS  Article  Google Scholar 

  31. 31.

    Nakamura, M. et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144, 5441–5449 (2003).

    CAS  Article  Google Scholar 

  32. 32.

    Seeman, E. & Delmas, P. D. Bone quality—the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250–2261 (2006).

    CAS  Article  Google Scholar 

  33. 33.

    Kramer, I. et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol. 30, 3071–3085 (2010).

    CAS  Article  Google Scholar 

  34. 34.

    Ominsky, M. S. et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 23, 672–682 (2008).

    CAS  Article  Google Scholar 

  35. 35.

    Zhang, L. et al. C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol. Lett. 3, 395–400 (2012).

    CAS  Article  Google Scholar 

  36. 36.

    Rachner, T. D. et al. Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in nonmetastatic breast cancer. Clin. Cancer Res. 25, 1369–1378 (2019).

    Article  Google Scholar 

Download references

Acknowledgements

We thank K. Miyazono, N. Komatsu, K. Kusubata, Y. Ogiwara, S. Nitta, K. Nagashima, M. Tsukasaki, M. Inoue, Y. Nakayama (The University of Tokyo), S. Sawa (Kyushu University), T. Nakashima (Tokyo Medical and Dental University) and M. Hattori (Tokyo Women’s Medical University) for thoughtful discussion and valuable technical assistance. This work was supported in part by a Practical Research Project for Rare/Intractable Diseases grant (JP17ek0109106) from the Japan Agency for Medical Research and Development; a Grant-in-Aid for Specially Promoted Research (15H05703), Young Scientists A (15H05653), Scientific Research B (16H05202 and 18H02919), Challenging Research (Pioneering) (17K19582) and the Japan Society for the Promotion of Science (JSPS) fellow (17J04280); Grants-in Aid for Research from the National Center for Global Health and Medicine (26-105 and 29-1001); The Japanese Society for Bone and Mineral Research Rising Stars Grant; and grants from Taiju Life Social Welfare Foundation, Astellas Research Support and Kobayashi Foundation for Cancer Research. T.A. was supported by a JSPS Research Fellowship for Young scientists.

Author information

Affiliations

Authors

Contributions

T.A. performed most of the experiments, interpreted the results and prepared the manuscript. K.O. designed the study, interpreted the results and contributed to the manuscript preparation. M.T. and T.N. contributed to analyses of the thymus. A.S. assisted with bone analyses. R.M. generated genetically modified cell lines. Y.N., K.H. and S.E. contributed to analysis of the bone metastasis. T.O. generated genetically modified mice. H.T. directed the project and wrote the manuscript.

Corresponding authors

Correspondence to Kazuo Okamoto or Hiroshi Takayanagi.

Ethics declarations

Competing interests

The Department of Osteoimmunology is an endowment department, supported with an unrestricted grant from AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical, MIKI HOUSE and Noevir.

Additional information

Peer review information: Primary Handling Editor: Pooja Jha.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Asano, T., Okamoto, K., Nakai, Y. et al. Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone. Nat Metab 1, 868–875 (2019). https://doi.org/10.1038/s42255-019-0104-1

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing